TY - JOUR
T1 - Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
AU - Amit-Vazina, M.
AU - Shishodia, S.
AU - Harris, D.
AU - Van, Q.
AU - Wang, M.
AU - Weber, D.
AU - Alexanian, R.
AU - Talpaz, M.
AU - Aggarwal, B. B.
AU - Estrov, Z.
PY - 2005/7/11
Y1 - 2005/7/11
N2 - Multiple myeloma (MM) accounts for 1% of all cancer deaths. Although treated aggressively, almost all myelomas eventually recur and become resistant to treatment. Atiprimod (2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate) has exerted anti-inflammatory activities and inhibited oeteoclast-induced bone resorption in animal models and been well tolerated in patients with rheumatoid arthritis in phase 1 clinical trials. Therefore, we investigated its activity in MM cells and its mechanism of action. We found that Atiprimod inhibited proliferation of the myeloma cell lines U266-B1, OCI-MY5, MM-1, and MM-1R in a time- and dose-dependent manner. Atiprimod blocked U266-B1 myeloma cells in the G0/G1 phase, preventing cell cycle progression. Furthermore, Atiprimod inhibited signal transducer and activator of transcription (STAT) 3 activation, blocking the signalling pathway of interleukin-6, which contributes to myeloma cell proliferation and survival, and downregulated the antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. Incubation of U266-B1 myeloma cells with Atiprimod induced apoptosis through the activation of caspase 3 and subsequent cleavage of the DNA repair enzyme poly(adenosine diphosphate-ribose) polymerase. Finally, Atiprimod suppressed myeloma colony-forming cell proliferation in fresh marrow cells from five patients with newly diagnosed MM in a dose-dependent fashion. These data suggest that Atiprimod has a role in future therapies for MM.
AB - Multiple myeloma (MM) accounts for 1% of all cancer deaths. Although treated aggressively, almost all myelomas eventually recur and become resistant to treatment. Atiprimod (2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate) has exerted anti-inflammatory activities and inhibited oeteoclast-induced bone resorption in animal models and been well tolerated in patients with rheumatoid arthritis in phase 1 clinical trials. Therefore, we investigated its activity in MM cells and its mechanism of action. We found that Atiprimod inhibited proliferation of the myeloma cell lines U266-B1, OCI-MY5, MM-1, and MM-1R in a time- and dose-dependent manner. Atiprimod blocked U266-B1 myeloma cells in the G0/G1 phase, preventing cell cycle progression. Furthermore, Atiprimod inhibited signal transducer and activator of transcription (STAT) 3 activation, blocking the signalling pathway of interleukin-6, which contributes to myeloma cell proliferation and survival, and downregulated the antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. Incubation of U266-B1 myeloma cells with Atiprimod induced apoptosis through the activation of caspase 3 and subsequent cleavage of the DNA repair enzyme poly(adenosine diphosphate-ribose) polymerase. Finally, Atiprimod suppressed myeloma colony-forming cell proliferation in fresh marrow cells from five patients with newly diagnosed MM in a dose-dependent fashion. These data suggest that Atiprimod has a role in future therapies for MM.
KW - Apoptosis
KW - Clonogenic assay
KW - Multiple myeloma
KW - Nuclear factor κB
KW - Signal transduction
UR - http://www.scopus.com/inward/record.url?scp=23044478114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23044478114&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6602637
DO - 10.1038/sj.bjc.6602637
M3 - Article
C2 - 15970928
AN - SCOPUS:23044478114
SN - 0007-0920
VL - 93
SP - 70
EP - 80
JO - British journal of cancer
JF - British journal of cancer
IS - 1
ER -